2025 Japan Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report
Description
The 2025 Japan Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Japan's Cell and Gene Therapy Manufacturing Services Market are Takeda Pharmaceutical, Astellas Pharma, Fujifilm Cellular Dynamics (part of FUJIFILM Holdings), and Thermo Fisher Scientific. Takeda Pharmaceutical and Astellas Pharma are leading Japanese pharmaceutical companies heavily involved in developing regenerative and gene therapies tailored to Japan’s aging population and chronic disease demand. Fujifilm Cellular Dynamics provides advanced manufacturing services including flexible bioreactor suites and cryopreservation facilities for cell therapies, supporting both clinical and commercial stages. Thermo Fisher Scientific contributes with innovative manufacturing equipment and closed systems to ensure high-yield, contamination-free production of gene and cell therapy products. These companies together leverage Japan's supportive regulatory environment and collaborations between pharma, academia, and biotech sectors to advance cutting-edge therapies.
Additionally, other key players with significant presence and influence include Catalent and Lonza, global leaders with operations facilitating gene and cell therapy manufacturing in Japan and Asia. Catalent offers turnkey manufacturing services supporting rare disease treatments, while Lonza provides robust infrastructure for viral vectors and allogeneic cell therapies. WuXi Advanced Therapies also expands capacity in Japan with AI-driven process optimizations. The growing pipeline of regenerative, oncologic, and rare disease therapies combined with strategic partnerships, such as Fujifilm’s UK expansion and domestic innovation clusters, strengthen Japan’s position in this competitive market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Japan's Cell and Gene Therapy Manufacturing Services Market are Takeda Pharmaceutical, Astellas Pharma, Fujifilm Cellular Dynamics (part of FUJIFILM Holdings), and Thermo Fisher Scientific. Takeda Pharmaceutical and Astellas Pharma are leading Japanese pharmaceutical companies heavily involved in developing regenerative and gene therapies tailored to Japan’s aging population and chronic disease demand. Fujifilm Cellular Dynamics provides advanced manufacturing services including flexible bioreactor suites and cryopreservation facilities for cell therapies, supporting both clinical and commercial stages. Thermo Fisher Scientific contributes with innovative manufacturing equipment and closed systems to ensure high-yield, contamination-free production of gene and cell therapy products. These companies together leverage Japan's supportive regulatory environment and collaborations between pharma, academia, and biotech sectors to advance cutting-edge therapies.
Additionally, other key players with significant presence and influence include Catalent and Lonza, global leaders with operations facilitating gene and cell therapy manufacturing in Japan and Asia. Catalent offers turnkey manufacturing services supporting rare disease treatments, while Lonza provides robust infrastructure for viral vectors and allogeneic cell therapies. WuXi Advanced Therapies also expands capacity in Japan with AI-driven process optimizations. The growing pipeline of regenerative, oncologic, and rare disease therapies combined with strategic partnerships, such as Fujifilm’s UK expansion and domestic innovation clusters, strengthen Japan’s position in this competitive market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
